Ovid Therapeutics Inc. (OVID) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $185.00K; Additional Paid in CapitalUSD $564.16M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-750.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $167.00K; Additional Paid in CapitalUSD $537.23M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-422.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $130.00K; Additional Paid in CapitalUSD $452.44M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-202.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $71.00K; Additional Paid in CapitalUSD $376.13M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-126.00K.
Ovid Therapeutics Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Additional Paid in Capital, Common Stock USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $185.00K | $564.16M | $-750.00K | $-353.71M | $209.89M | 3 month · $1.43M | (m) |
| 2026-03-31 | (m) | $167.00K | $537.23M | $-422.00K | $-338.70M | $198.27M | 3 month · $1.05M | (m) |
| 2025-12-31 | $0.00 | $130.00K | $452.44M | $-202.00K | $-321.71M | $130.66M | 12 month · $4.81M | (m) |
| 2025-09-30 | $0.00 | $71.00K | $376.13M | $-126.00K | $-331.38M | $44.70M | 3 month · $1.11M | (m) |
| 2025-06-30 | $0.00 | $71.00K | $375.00M | $-69.00K | $-319.22M | $55.79M | 3 month · $1.22M | (m) |
| 2025-03-31 | $0.00 | $71.00K | $373.79M | $-47.00K | $-314.53M | $59.28M | 3 month · $1.28M | (m) |
| 2024-12-31 | $0.00 | $71.00K | $372.49M | $-35.00K | $-304.30M | $68.23M | 12 month · $6.28M | (m) |
| 2024-09-30 | $0.00 | $71.00K | $371.23M | $36.00K | $-295.05M | $76.29M | 3 month · $1.31M | (m) |
| 2024-06-30 | $0.00 | $71.00K | $369.88M | $-12.00K | $-281.04M | $88.90M | 3 month · $1.74M | (m) |
| 2024-03-31 | $0.00 | $71.00K | $367.79M | $-19.00K | $-289.56M | $78.28M | 3 month · $1.97M | (m) |
| 2023-12-31 | $0.00 | $71.00K | $365.59M | $1.00K | $-277.87M | $87.80M | 12 month · $7.29M | (m) |
| 2023-09-30 | $1.00 | $70.68K | $363.77M | $-3.88K | $-262.54M | $101.29M | 3 month · $1.63M | (m) |
| 2023-06-30 | $1.00 | $70.60K | $361.91M | $5.21K | $-251.29M | $110.70M | 3 month · $1.95M | (m) |
| 2023-03-31 | $1.00 | $70.49K | $359.75M | $5.63K | $-238.88M | $120.95M | 3 month · $1.92M | (m) |
| 2022-12-31 | $1.00 | $70.47K | $357.77M | $-42.19K | $-225.53M | $132.27M | 12 month · $6.56M | (m) |
| 2022-09-30 | $1.00 | $70.47K | (m) | $-82.79K | $-214.02M | $142.05M | 3 month · $1.78M | $356.08M |
| 2022-06-30 | $1.00 | $70.41K | (m) | $-90.13K | $-202.05M | $152.15M | 3 month · $1.72M | $354.22M |
| 2022-03-31 | $1.00 | $70.37K | (m) | (m) | $-187.47M | $165.00M | 3 month · $1.32M | $352.39M |
| 2021-12-31 | $1.00 | $70.36K | $351.03M | $0.00 | $-171.36M | $179.75M | 12 month · $5.05M | $351.03M |
| 2021-09-30 | $1.00 | $68.02K | (m) | (m) | $-145.36M | $197.02M | 3 month · $1.16M | $342.31M |
| 2021-06-30 | $1.00 | $67.83K | (m) | (m) | $-133.97M | $206.71M | 3 month · $1.26M | $340.61M |
| 2021-03-31 | $1.00 | $67.79K | (m) | (m) | $-118.18M | $221.11M | 3 month · $1.32M | $339.23M |
| 2020-12-31 | $3.00 | $65.74K | (m) | (m) | $-294.19M | $43.63M | 12 month · $7.53M | $337.76M |
| 2020-09-30 | $6.00 | $63.44K | (m) | (m) | $-272.16M | $63.64M | 3 month · $2.62M | $335.74M |
| 2020-06-30 | $6.00 | $57.08K | (m) | (m) | $-255.74M | $30.48M | 3 month · $1.56M | $286.16M |
| 2020-03-31 | $8.00 | $54.75K | (m) | $65.70K | $-233.19M | $51.44M | 3 month · $1.30M | $284.51M |
| 2019-12-31 | $8.00 | $54.71K | (m) | $2.47K | $-213.16M | $70.02M | 12 month · $5.21M | $283.12M |
| 2019-09-30 | $4.00 | $37.47K | (m) | (m) | $-196.19M | $30.05M | 3 month · $1.18M | $226.20M |
| 2019-06-30 | $3.00 | $38.69K | (m) | (m) | $-179.55M | $45.44M | 3 month · $1.25M | $224.95M |
| 2019-03-31 | $3.00 | $38.69K | (m) | $1.35K | $-166.50M | $57.25M | 3 month · $1.64M | $223.70M |
| 2018-12-31 | (m) | $24.65K | (m) | $-1.83K | $-152.70M | $38.81M | 12 month · $7.06M | $191.48M |
| 2018-09-30 | (m) | $24.65K | (m) | $-4.67K | $-139.80M | $49.97M | 3 month · $1.69M | $189.75M |
| 2018-06-30 | (m) | $24.63K | (m) | $-16.02K | $-126.83M | $61.12M | 3 month · $1.84M | $187.94M |
| 2018-03-31 | (m) | $24.62K | (m) | $-35.91K | $-113.90M | $72.09M | 3 month · $1.79M | $186.00M |
| 2017-12-31 | (m) | $24.61K | $184.13M | (m) | $-100.72M | $83.44M | 12 month · $6.40M | $184.13M |
| 2017-09-30 | (m) | $24.60K | $182.69M | (m) | $-89.76M | $92.96M | 9 month · $4.99M | (m) |
| 2017-06-30 | (m) | $24.60K | $181.31M | (m) | $-80.40M | $100.94M | 6 month · $3.61M | (m) |
| 2017-03-31 | (m) | $9.84K | $112.46M | (m) | $-70.15M | $42.34M | 3 month · $1.42M | (m) |
| 2016-12-31 | (m) | $9.84K | $85.19M | (m) | $-35.91M | $49.29M | 12 month · $3.64M | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | $68.07M | 12 month · $1.46M | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | $4.74M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |